Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00057174 · ClinicalTrials.gov registry record · NA
Economic Impact of Guidelines for Gastroesophageal Reflux Disease
A NA study of Gastroesophageal Reflux Disease and Health Economics, sponsored by US Department of Veterans Affairs.
- Completed
- Registry status
- NA
- Development phase
- 484
- Enrollment target
- 1
- Study location
NCT00057174 is a NA study of Gastroesophageal Reflux Disease and Health Economics that has completed, run by US Department of Veterans Affairs. The registered enrollment target is 484 participants, above the 327-participant average among 24 other Gastroesophageal Reflux Disease trials with a reported enrollment target (48% higher). The trial reports 1 study location across 1 state.
The verdict
NCT00057174, a NA study of Gastroesophageal Reflux Disease and Health Economics, has completed, sponsored by US Department of Veterans Affairs.
- COMPLETED
- Registry status
- NA
- Development phase
- 484 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a series of two prospective studies based on the Department of Veterans Affairs drug treatment guideline for the pharmacologic management of gastroesophageal reflux disease. Our hypothesis is that novel strategies for medical management of gastroesophageal reflux disease (GERD) can decrease resource utilization without adversely affecting patient quality of life. The strategies tested in this project included 1) step-down management, whereby patients rendered asymptomatic on proton pump inhibitors (PPIs) are treated with less expensive medication, and 2) intermittent therapy, defined as administration of medication only for recurrence of GERD symptoms. We chose to examine an intermittent strategy of PPI administration since in addition to the VA guideline requiring step-down therapy, over-the-counter PPIs administered by intermittent therapy became available for use by patients during the study period.
Conditions Studied
Interventions
- DRUG Disease management of gastroesophageal reflux disease
Study Locations (1)
Michigan
- VA Ann Arbor Healthcare System, Ann Arbor, MI - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 484 participants |
| Est. Completion | 2004-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00057174
The ClinicalTrials.gov registry entry for NCT00057174 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 484 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 327-participant average among 24 other Gastroesophageal Reflux Disease trials with a reported enrollment target (48% higher). The listed sponsor is US Department of Veterans Affairs, which has 632 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Gastroesophageal Reflux Disease appearing as the primary indexed condition, and to 1 intervention - of which Disease management of gastroesophageal reflux disease is the first listed.
NCT00057174 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.
Frequently Asked Questions
What is clinical trial NCT00057174 about?
NCT00057174 is a clinical study titled "Economic Impact of Guidelines for Gastroesophageal Reflux Disease". This is a series of two prospective studies based on the Department of Veterans Affairs drug treatment guideline for the pharmacologic management of gastroesophageal reflux disease. Our hypothesis is that novel strategies for medical management of gastroesophageal reflux disease (GERD) can decrease ...
What is the current status of trial NCT00057174?
This trial is currently completed. It is a NA study. The enrollment target is 484 participants. Estimated completion is 2004-06.
What conditions does trial NCT00057174 study?
This clinical trial studies the following conditions: Gastroesophageal Reflux Disease, Health Economics.
What interventions are being tested in trial NCT00057174?
The interventions under investigation include: Disease management of gastroesophageal reflux disease (DRUG).
Who is sponsoring clinical trial NCT00057174?
This trial is sponsored by US Department of Veterans Affairs, which has 632 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00057174 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastroesophageal Reflux Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Mechanistic and Clinical Outcomes of a Surgical Innovation Aimed at Minimizing GERD Associated With VSG (INNOVATE-VSG)
RECRUITING · NA
-
Randomized EsophyX Versus Sham / Placebo Controlled TIF Trial: The RESPECT Study
COMPLETED · NA
-
Esophageal Cytology With FISH in Detecting Esophageal Cancer
COMPLETED · NA
-
Comparison of Laparoscopic Hill and Laparoscopic Nissen Anti-Reflux Procedures
COMPLETED · NA
-
Swallowable Sponge Cell Sampling Device and Next Generation Sequencing in Detecting Esophageal Cancer in Patients With Low or High Grade Dysplasia, Barrett Esophagus, or Gastroesophageal Reflux Disease
COMPLETED · NA
-
Progression of Gastroesophageal Reflux Disease and Barrett's Esophagus and the Creation of a Barrett's Registry
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.